trending Market Intelligence /marketintelligence/en/news-insights/trending/gvkf3ojarmsjopda66qx-a2 content esgSubNav
In This List

Lawsuit against Intercept Pharmaceutical directors dismissed by US court

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Lawsuit against Intercept Pharmaceutical directors dismissed by US court

Intercept Pharmaceuticals Inc. said a U.S. court granted a motion to dismiss a shareholder lawsuit which alleged that company directors breached their fiduciary duty.

The Supreme Court of the State of New York, County of New York dismissed the suit, Solak v. Fundaro, et al., which was filed August 2017, purportedly on behalf of the company.

The suit alleged that company directors violated the company's nonexecutive director compensation practices.

The New York-based biopharmaceutical company said the ruling is subject to appeal.